EW · XBRL financial data

Edwards Lifesciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (EW's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	1,481	1,266	1,598	1,386	1,354	1,386	1,413	1,532	1,553	1,570*	1,649	1,741
Cost of goods and services sold	350	357*	386	285	263	292*	302	344	345	343*	363	392
Gross profit	1,131	1,015	1,213	1,101	1,092	1,094	1,111	1,188	1,208	—	1,286	1,349
Research and development	270	270*	285	273	253	271*	255	276	281	268*	263	279
Selling, general and administrative	440	480*	490	451	421	492*	466	502	515	603*	522	561
Other operating income (expense)	0	0*	0	0	(22)	23*	19	21	13	14*	14	11
Operating income (loss)	418	400*	388	369	351	313*	395	411	307	151*	478	513
Interest income	—	year only	—	—	—	year only	37	37	—	year only	34	30
Interest expense	—	year only	—	—	—	year only	—	—	—	year only	—	—
Other income (expense)	6	5*	5	2	28	33*	3	(1)	3	3*	72	17
Income tax expense (benefit)	56	52*	58	20	41	45*	70	64	56	26*	78	278
Net income (loss)	385	370	352	366	3,071	386	358	333	291	91*	381	242
Earnings per share, basic USD per share	0.63	0.61	0.58	0.61	5.14	0.65	0.61	0.57	0.50	0.16*	0.66	0.42
Earnings per share, diluted USD per share	0.63	0.61	0.58	0.61	5.13	0.65	0.61	0.56	0.50	0.16*	0.66	0.42
Weighted average shares, basic millions of shares	607	605*	602	602	597	590*	587	587	585	581*	579	576
Weighted average shares, diluted millions of shares	610	607*	604	604	598	591*	588	588	586	582*	581	578

Balance sheet

CSV

Fiscal quarters (EW's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,410	1,144	1,225	1,645	3,676	3,045	3,141	3,273	2,686	2,938	2,446	2,907
Short-term investments	454	501	473	345	770	931	758	789	1,156	1,288	1,226	1,346
Accounts receivable	740	775	818	778	716	609	669	697	693	660	776	770
Inventory	1,032	1,168	1,207	1,025	1,104	1,087	1,114	1,142	1,141	1,126	1,119	1,131
Total current assets	4,068	4,036	4,171	4,516	6,728	6,285	6,213	6,577	6,359	6,739	6,229	6,819
Property and equipment, net	1,681	1,749	1,768	1,640	1,676	1,686	1,698	1,727	1,743	1,812	1,823	1,842
Right-of-use asset	91	94	98	93	104	98	97	99	97	103	99	100
Goodwill	1,297	1,254	1,253	1,151	1,605	1,777	1,779	1,777	1,769	1,769	1,820	1,951
Total assets	9,371	9,363	9,736	10,099	12,971	13,055	13,022	13,489	13,272	13,697	13,321	13,867
Accounts payable	191	201	212	186	173	197	172	162	165	228	181	211
Total current liabilities	1,239	1,195	1,111	1,217	1,944	1,505	1,395	1,405	1,588	1,814	1,409	1,508
Long-term debt	597	597	597	597	598	598	598	598	598	598	599	599
Lease liability, non-current	70	73	77	74	85	79	78	79	75	83	80	82
Total liabilities	2,644	2,644	2,550	2,595	3,360	2,992	2,831	2,882	3,067	3,360	2,994	3,142
Retained earnings	8,623	8,992	9,344	9,711	12,781	13,167	13,525	13,858	14,149	14,241	14,621	14,863
Total stockholders' equity	6,658	6,650	7,118	7,437	9,546	9,998	10,129	10,545	10,205	10,338	10,328	10,618
Total liabilities and equity	9,371	9,363	9,736	10,099	12,971	13,055	13,022	13,489	13,272	13,697	13,321	13,867
Common shares outstanding (cover page) millions of shares	607	601	603	602	590	588	587	587	580	581	576	576

Cash flows

CSV

Fiscal quarters (EW's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	385	370	352	366	3,071	386	358	333	291	91*	381	242
Stock-based compensation	33*	31*	45	44*	42*	32*	40	38*	41*	39*	45	42*
Depreciation and amortization	37*	37*	39	40*	35*	43*	37	38*	39*	43*	41	43*
Net cash from operating activities	412*	137*	(54)	372*	352*	(128)*	280	290*	574*	451*	44	652*
Purchases of property and equipment	55*	88*	65	85*	52*	50*	56	49*	58*	97*	65	67*
Net cash from investing activities	89*	14*	63	125*	2,702*	(577)*	85	(172)*	(428)*	(198)*	(93)	(193)*
Share repurchases	174*	448*	0	158*	901*	100*	259	6*	589*	41*	422	153*
Proceeds from long-term debt	—	year only	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	(143)*	(413)*	62	(97)*	(977)*	29*	(258)	53*	(740)*	(11)*	(451)	(0)*
Net change in cash	366*	(266)*	81	429*	2,025*	(625)*	90	141*	(595)*	245*	(492)	462*

Compare with peers

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Edwards Lifesciences	2,907	1,741	652*	576.4M	—	Q2 FY26 10-QJun 30, 2026
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	—	Q3 FY26 10-QJun 30, 2026
3M	4,835	6,584	486*	516.7M	—	Q3 FY26 10-QSep 30, 2026
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.